← Back to Search

Tau PET Imaging for Primary Progressive Aphasia

Phase 1
Recruiting
Led By Emily Rogalski, Ph.D.
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new PET scan to map tau pathology in the brains of people with Primary Progressive Aphasia. If successful, this could help researchers better understand and treat this disease.

Who is the study for?
This trial is for individuals with Primary Progressive Aphasia and other related dementias. Participants must not be pregnant, breastfeeding, or undergoing clinical radiation treatments.Check my eligibility
What is being tested?
The study aims to map tau protein build-up in the brain using a PET scan with a tracer called AV-1451. It will document where and how much tau protein is present in patients with Primary Progressive Aphasia.See study design
What are the potential side effects?
While the PET scan itself is generally safe, potential side effects from the AV-1451 tracer may include allergic reactions or discomfort at the injection site.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tau levels in PPA participants

Side effects data

From 2016 Phase 4 trial • 218 Patients • NCT02681172
2%
Injection Site Pain
2%
Injection Site Paraesthesia
1%
Injection Site Haematoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Safety Analysis Set

Trial Design

1Treatment groups
Experimental Treatment
Group I: AV-1451 RecipientsExperimental Treatment2 Interventions
Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-AV-1451
2016
Completed Phase 2
~120
PET
2009
Completed Phase 4
~700

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,585 Previous Clinical Trials
917,161 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,667 Previous Clinical Trials
28,004,824 Total Patients Enrolled
Emily Rogalski, Ph.D.Principal Investigator - Northwestern University
Northwestern University
1 Previous Clinical Trials
95 Total Patients Enrolled

Media Library

PET Clinical Trial Eligibility Overview. Trial Name: NCT03283449 — Phase 1
Primary Progressive Aphasia Research Study Groups: AV-1451 Recipients
Primary Progressive Aphasia Clinical Trial 2023: PET Highlights & Side Effects. Trial Name: NCT03283449 — Phase 1
PET 2023 Treatment Timeline for Medical Study. Trial Name: NCT03283449 — Phase 1
Primary Progressive Aphasia Patient Testimony for trial: Trial Name: NCT03283449 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this investigation still accepting volunteers?

"Affirmative. Per the information found on clinicaltrials.gov, this medical trial is presently gathering participants; it was initially posted in February 2016 and has been recently updated as of October 4th 2022. 70 individuals need to be recruited by 1 site for full completion of the study."

Answered by AI

Has positron emission tomography been used in any prior experiments?

"Currently, 3 clinical trials are researching PET. None of these tests have advanced to Phase 3 yet. While most studies for this treatment are situated in Rochester, Minnesota, other locations across the country contain active research sites too."

Answered by AI

What is the total expected enrollment for this medical trial?

"Affirmative. According to the information found on clinicaltrials.gov, this trial is still recruiting participants and has done so since its inception in February 1st 2016. 70 patients are being sought after at a single medical centre."

Answered by AI

Has the Federal Drug Administration officially endorsed positron emission tomography?

"Our team at Power has rated PET's safety a 1 due to the limited clinical data that exists for its efficacy and security. This is in line with it being categorized as a Phase 1 trial."

Answered by AI

Is this clinical trial open to individuals under 35 years of age?

"To be considered for this specific clinical trial, applicants must have attained the age of majority and be below 100 years old. Additionally, there are 44 trials available to those not yet 18 and 837 experiments open to individuals above 65."

Answered by AI

What conditions is positron emission tomography imaging utilized to diagnose?

"Positron Emission Tomography can be utilized to treat a variety of conditions, such as Chronic Traumatic Encephalopathy (CTE) and Alzheimer's disease (AD)."

Answered by AI

Am I able to partake in this medical study?

"Patient qualifications for this clinical trial necessitate a diagnosis of Alzheimer's disease and an age between 20-100. The researchers aim to recruit 70 participants in total."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
Arizona
What site did they apply to?
Cognitive Neurology and Alzheimer's Disease Center - Northwestern University
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I have tried no drugs for memory loss.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Tau PET Imaging in Atypical Dementias
Emily Rogalski 2016. "Tau PET Imaging in Atypical Dementias". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03283449.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top